Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.190
-0.020 (-1.65%)
At close: Jun 20, 2025, 4:00 PM
1.184
-0.006 (-0.48%)
After-hours: Jun 20, 2025, 6:36 PM EDT
Fate Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Fate Therapeutics stock have a consensus rating of "Hold" and an average price target of $3.83, which forecasts a 221.85% increase in the stock price over the next year. The lowest target is $2 and the highest is $5.
Price Target: $3.83 (+221.85%)
Analyst Consensus: Hold
* Price targets were last updated on May 14, 2025.
Analyst Ratings
The average analyst rating for Fate Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 0 | 0 |
| Buy | 2 | 2 | 1 | 1 | 2 | 1 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 9 | 9 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 12, 2025 |
| Barclays | Barclays | Buy Maintains $10 → $2 | Buy | Maintains | $10 → $2 | +68.07% | May 14, 2025 |
| Baird | Baird | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +236.13% | May 14, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 14, 2025 |
| Stifel | Stifel | Hold Maintains $5 → $3 | Hold | Maintains | $5 → $3 | +152.10% | Mar 6, 2025 |
Financial Forecast
Revenue This Year
4.75M
from 13.63M
Decreased by -65.12%
Revenue Next Year
2.95M
from 4.75M
Decreased by -37.95%
EPS This Year
-1.35
from -1.64
EPS Next Year
-1.32
from -1.35
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.3M | 14.3M | 14.3M | ||
| Avg | 4.8M | 3.0M | 2.8M | ||
| Low | 264,600 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.0% | 200.4% | 384.1% | ||
| Avg | -65.1% | -37.9% | -5.7% | ||
| Low | -98.1% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.10 | -1.01 | -0.65 | ||
| Avg | -1.35 | -1.32 | -1.20 | ||
| Low | -1.63 | -1.74 | -1.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.